EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Use of Glucagon‐Like Peptide 1 Receptor Agonists and the Associated Risk of Hospitalisation in Bipolar Disorder, From a Nationwide Cohort, 2009–2024

Heidi Taipale, Mark Taylor iD, Markku Lähteenvuo iD, Ellenor Mittendorfer-Rutz, Antti Tanskanen, Jari Tiihonen

Acta Psychiatrica Scandinavica · 2026

DOI: 10.1111/acps.70120 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Psychiatrica Scandinavica, 2026. Verfasst von Heidi Taipale und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland. Hauptthemen laut MEDLINE: Bipolar Disorder, Glucagon-Like Peptide-1 Receptor Agonists, Hospitalization, Hypoglycemic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sigrid Juselius Foundation, Jane and Aatos Erkko Foundation, Finnish Ministry of Social Affairs and Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Diabetes, obesity and bipolar disorder often co‐occur and may have shared pathophysiology. Glucagon‐like peptide 1 receptor agonists (GLP‐1RA) treat diabetes and obesity but their impact on bipolar disorder is unknown. In this era of stagnated pharmacotherapy, we examined psychiatric hospitalisation and absence from work due to sick leave as potential measures of relapse in people diagnosed with bipolar disorder who were also prescribed antidiabetic medications, including GLP‐1RA.

Methods

The study cohort was derived from the National Swedish Registers and included all people with a diagnosis of bipolar disorder who used any antidiabetic medication, between the years 2009 and 2024. GLP ‐ 1RA individually and as a group were compared with non‐use of GLP ‐ 1RA , and directly with other second‐line antidiabetic medications. A within‐individual design was utilised for all comparisons to reduce confounding. The main outcome was psychiatric hospitalisation for any reason, with secondary outcomes being psychiatric hospitalisation after a relapse of bipolar disorder, and sick leave due to psychiatric reasons. Within‐individual stratified Cox models with adjusted hazard ratios ( aHRs ) and 95% confidence intervals ( CIs ) were used.

Results

14,694 people were included in the study, of whom 5200 used GLP ‐ 1RA . Semaglutide was associated with a 21% ( aHR 0.79, 95% CI 0.69–0.91) lower risk of psychiatric hospitalisation compared with non‐use of GLP ‐ 1RA in that same individual. Liraglutide and dulaglutide were not specifically associated with a lower hospitalisation risk. Semaglutide was also linked to a 17% ( aHR 0.83, 95% CI 0.69–0.99) lower risk of relapse of bipolar disorder. Absences from work due to sick leave were not significantly associated with the specific antidiabetic medications studied.

Conclusion

In people with both bipolar disorder and diabetes and/or obesity, the use of semaglutide was linked to lower rates of psychiatric hospitalisation compared with time periods when GLP‐1RA were not used by that individual. Liraglutide and dulaglutide were not associated with reduced psychiatric hospitalisation, implying this is not a class effect. This finding with semaglutide should be further tested in a randomised controlled trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bipolar DisorderGlucagon-Like Peptide-1 Receptor AgonistsHospitalizationHypoglycemic AgentsDiabetes Mellitus, Type 2HumansSwedenFemaleMaleSemaglutideRegistriesMiddle AgedAdultCohort StudiesSick LeaveLiraglutideObesityGlucagon-Like PeptidesImmunoglobulin Fc FragmentsRecombinant Fusion Proteins

Stichwörter der Autor:innen

GLP‐1RAbipolarhospitalisation

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsSemaglutideHypoglycemic AgentsLiraglutidedulaglutideGlucagon-Like PeptidesImmunoglobulin Fc FragmentsRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland.
  • Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Centre for Psychiatry Research, Stockholm City Council, Stockholm, Sweden.
  • School of Pharmacy, University of Eastern Finland, Kuopio, Finland.
  • School of Medicine and Dentistry, Griffith University, Gold Coast, Australia.
  • The Edinburgh Practice, Edinburgh, UK.

ORCID-Profile: Mark Taylor, Markku Lähteenvuo

Förderung

  • Sigrid Juselius Foundation
  • Jane and Aatos Erkko Foundation
  • Finnish Ministry of Social Affairs and Health
  • Swedish Research Council
  • Jane ja Aatos Erkon Säätiö
  • Vetenskapsrådet

Zitieren

APA

Taipale, H., Taylor, M., Lähteenvuo, M., Mittendorfer-Rutz, E., Tanskanen, A., & Tiihonen, J. (2026). Use of Glucagon‐Like Peptide 1 Receptor Agonists and the Associated Risk of Hospitalisation in Bipolar Disorder, From a Nationwide Cohort, 2009–2024. Acta Psychiatrica Scandinavica. https://doi.org/10.1111/acps.70120

Vancouver

Taipale H, Taylor M, Lähteenvuo M, Mittendorfer-Rutz E, Tanskanen A, Tiihonen J. Use of Glucagon‐Like Peptide 1 Receptor Agonists and the Associated Risk of Hospitalisation in Bipolar Disorder, From a Nationwide Cohort, 2009–2024. Acta Psychiatrica Scandinavica. 2026. doi:10.1111/acps.70120

BibTeX
@article{Taipale2026,
  author = {Taipale, Heidi and Taylor, Mark and Lähteenvuo, Markku and Mittendorfer-Rutz, Ellenor and Tanskanen, Antti and Tiihonen, Jari},
  title = {Use of Glucagon‐Like Peptide 1 Receptor Agonists and the Associated Risk of Hospitalisation in Bipolar Disorder, From a Nationwide Cohort, 2009–2024},
  journal = {Acta Psychiatrica Scandinavica},
  year = {2026},
  doi = {10.1111/acps.70120}
}
Kostenlos starten →